ArticleScientific reports2025
The oncogenic role of TIMM8A in cancer and the mechanistic insights into the function in breast cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Loss of TIMM8A Inhibits Breast Cancer Progression Through Promoting HSPA9 Ubiquitination and Degradation via Competitive Interaction with RNF4.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The expression of TIMM8A, a molecular chaperone involved in mitochondrial protein translocation, was observed to be significantly elevated in various tumor types. However, the specific role of TIMM8A in cancer development and its underlying molecular mechanism remains inadequately understood. In this study, our primary objective was to investigate the functional implications of TIMM8A in breast cancer development, while also assessing its expression levels and prognostic relevance in pan-cancer. Notably, TIMM8A exhibited high expression in nearly 33 different cancer types, which was consistently associated with unfavorable clinical outcomes. In breast cancer, TIMM8A exhibited a strong association with prognosis and demonstrated its potential as an independent prognostic indicator. Additionally, the inhibition of TIMM8A effectively impeded the proliferation of MCF-7 and MDA-MB-231 cells, while also suppressing their migratory and invasive capabilities in vitro. Mechanistically, the downregulation of NF-κB p65, upregulation of pro-apoptotic proteins, and regulation of EMT-related proteins were observed upon TIMM8A knockdown. Furthermore, the over-expression of miR-10b-5p effectively hindered the expression of TIMM8A. Collectively, TIMM8A, a critical oncogene, was regulated by miR-10b-5p and could activate NF-κB signaling cascade response, promote apoptosis inhibition and regulate EMT-related protein expression, thereby stimulating proliferation, migration, and invasion of breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.